|
Gene: CLSTN2 |
Gene summary for CLSTN2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CLSTN2 | Gene ID | 64084 |
Gene name | calsyntenin 2 | |
Gene Alias | ALC-GAMMA | |
Cytomap | 3q23 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q9H4D0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64084 | CLSTN2 | S014 | Human | Liver | HCC | 6.80e-12 | 5.15e-01 | 0.2254 |
64084 | CLSTN2 | S015 | Human | Liver | HCC | 9.93e-07 | 4.33e-01 | 0.2375 |
64084 | CLSTN2 | S016 | Human | Liver | HCC | 1.36e-20 | 5.89e-01 | 0.2243 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CLSTN2 | SNV | Missense_Mutation | c.566N>A | p.Ser189Tyr | p.S189Y | Q9H4D0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
CLSTN2 | SNV | Missense_Mutation | c.253N>T | p.Ile85Phe | p.I85F | Q9H4D0 | protein_coding | deleterious(0) | possibly_damaging(0.879) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
CLSTN2 | SNV | Missense_Mutation | rs757739003 | c.1795N>T | p.Arg599Trp | p.R599W | Q9H4D0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR |
CLSTN2 | SNV | Missense_Mutation | rs529034321 | c.245N>T | p.Ala82Val | p.A82V | Q9H4D0 | protein_coding | deleterious(0) | possibly_damaging(0.758) | TCGA-AR-A1AR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Docetaxel | PD |
CLSTN2 | SNV | Missense_Mutation | rs759107918 | c.956N>T | p.Ser319Phe | p.S319F | Q9H4D0 | protein_coding | deleterious(0) | benign(0.208) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CLSTN2 | SNV | Missense_Mutation | c.145C>T | p.His49Tyr | p.H49Y | Q9H4D0 | protein_coding | deleterious(0) | possibly_damaging(0.502) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
CLSTN2 | SNV | Missense_Mutation | novel | c.1052G>T | p.Ser351Ile | p.S351I | Q9H4D0 | protein_coding | tolerated(0.06) | benign(0.276) | TCGA-C8-A26X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
CLSTN2 | SNV | Missense_Mutation | novel | c.1227N>A | p.Met409Ile | p.M409I | Q9H4D0 | protein_coding | tolerated(0.16) | benign(0.018) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
CLSTN2 | SNV | Missense_Mutation | c.145N>T | p.His49Tyr | p.H49Y | Q9H4D0 | protein_coding | deleterious(0) | possibly_damaging(0.502) | TCGA-D8-A1XJ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
CLSTN2 | SNV | Missense_Mutation | c.1303N>A | p.Asp435Asn | p.D435N | Q9H4D0 | protein_coding | deleterious(0.02) | possibly_damaging(0.767) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |